Status:
COMPLETED
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
Lead Sponsor:
Verve Therapeutics, Inc.
Conditions:
Heterozygous Familial Hypercholesterolemia
Atherosclerotic Cardiovascular Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
VT-1001 is an open-label, phase 1b, single-ascending dose study that will evaluate the safety of VERVE-101 administered to patients with heterozygous familial hypercholesterolemia (HeFH), atherosclero...
Eligibility Criteria
Inclusion
- Male and/or female participants 18 up to 75 years at time of signing of informed consent
- Female participants not of child-bearing potential
- Diagnosis of HeFH
- Established ASCVD
Exclusion
- Active or history of chronic liver disease
- Current treatment with PCSK9 monoclonal antibody therapy
- Current or past treatment with inclisiran
- Clinically significant or abnormal laboratory values as defined by the protocol
Key Trial Info
Start Date :
July 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2025
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT05398029
Start Date
July 5 2022
End Date
February 14 2025
Last Update
May 8 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Study Center
Auckland, New Zealand
2
Clinical Study Center
Christchurch, New Zealand
3
Clinical Study Center
London, United Kingdom